Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation: A case report
Despite advancements in the treatment of diffuse large B-cell lymphoma, including CAR T-cell therapy, TP53 mutations remain a significant negative prognostic factor in patients with relapsed/refractory diffuse large B-cell lymphoma. The combination of autologous stem cell transplantation and CAR T-cell therapy may enhance long-term prognosis and reduce adverse effects, including severe cytokine release syndrome. This case report presents a 41-year-old man with relapsed/refractory diffuse large B-cell lymphoma harboring TP53 mutations who underwent autologous stem cell transplantation combined with CD19 CAR T-cell therapy. Two years posttreatment, the patient remains in sustained complete remission, highlighting the potential efficacy of this combination approach for relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation.
基金：
Undergraduate Scientific Research Training Program of Capital Medical University [XSKY2024]
第一作者机构：[1]Capital Med Univ, Xuanwu Hosp, Dept Hematol, Beijing 100053, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Cai Ziyi,Zou Dongmei,Ma Qiang,et al.Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation: A case report[J].SAGE OPEN MEDICAL CASE REPORTS.2025,13:doi:10.1177/2050313X241306236.
APA：
Cai, Ziyi,Zou, Dongmei,Ma, Qiang,Sun, Wanling&Guo, Yixian.(2025).Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation: A case report.SAGE OPEN MEDICAL CASE REPORTS,13,
MLA：
Cai, Ziyi,et al."Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation: A case report".SAGE OPEN MEDICAL CASE REPORTS 13.(2025)
